Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ZVRA

Zevra Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ZVRA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.94

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:35 UTC.

What Zevra Therapeutics, Inc. does

Zevra Therapeutics is a commercial-stage company focused on developing and commercializing therapies for rare diseases. The company's lead product, MIPLYFFA, received FDA approval for treating Niemann-Pick disease type C and became available for patient use in the United States; the company also commercializes OLPRUVA for urea cycle disorders and is advancing celiprolol in clinical trials for Vascular Ehlers-Danlos syndrome.

Summarized from Zevra Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.94
Return on equity53.82%
Debt/equity0.40

Revenue, margins & earnings

FY2021: net loss $9M on revenue $29M$29MFY2021FY2022: net loss $27M on revenue $10M$10MFY2022FY2023: net loss $46M on revenue $27M$27MFY2023FY2024: net loss $106M on revenue $24M$24MFY2024FY2025 Revenue: $106M — margin split not shown (non-operating gains)$106MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-13
  • 2026-10-13President and CEOSale-20,000$224.9K
  • 2026-10-13President and CEORestricted Stock UnitOption exercise-50,000—
  • 2026-10-13President and CEOOption exercise50,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Zevra Therapeutics, Inc. do?

Zevra Therapeutics is a commercial-stage company focused on developing and commercializing therapies for rare diseases.

When did ZVRA last file with the SEC?

Zevra Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-05. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:35 UTC. This page is also available as JSON at /api/data?ticker=ZVRA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ZVRA and 5,000+ tickers.

Create a free account — keep ZVRA
For your agent
GET /api/data?ticker=ZVRA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt